A Phase 2 interventional study of ECP (performed on Themos UVAR-XTS or external UVA irradiator after cell collection by apheresis) in Graft Versus Host Disease, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 0 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by University Hospital, Clermont-Ferrand · Phase 2, Interventional, and Treatment
How we know · 2 judgments
Sauret A, Rabiau N, Rochette E, Greze V, Halle P, Ouachee M, Dalle JH, Seror E, Serraz D, Yakouben K, Adjaoud D, Pagnier A, Marie-Cardine-Bobbia A, Oudot C, Cu…PubMed 26855157 ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Graft vs Host Disease with a site in France — 10 open to participants now, 14 under way, 4 of them phase 3. Graft vs Host Disease · France.
Among the 54 studies in Graft vs Host Disease with a site in France, this one is the 37th largest by enrollment of the 47 interventional ones that give a count, is one of 2 that started in 2009, is one of 16 in phase 2, and was the 6th registered.
804 studies on the registry are indexed under Graft vs Host Disease; 147 are open to participants now.
Browse Graft vs Host Disease studies →10 of the 54 studies in Graft vs Host Disease with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Bambino Gesù Hospital and Research Institute · Sites in France, Austria, Czechia and 6 more countries
Ages 3 mo–25 yrs
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 18–70
Hospices Civils de Lyon · Sites in France
Ages 2+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 101 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 40 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.
This study: 0 Years to 30 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 22 · Phase 3 17 · Phase 4 3
First in 2002; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 35 across 639 interventional studies indexed under Graft vs Host Disease.
Median enrollment 65 across the 47 interventional studies, 30 across the 5 observational. Of the 34 that completed or were terminated, 13 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 54 have an industry lead sponsor. The 10 most frequent:
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.
University Hospital, Clermont-Ferrand has 3 studies filed under Graft vs Host Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in Graft vs Host Disease with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04629833Phase 3medac GmbHTreatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy | 2027-08 |
| NCT03229200Pharmacyclics Switzerland GmbHExtended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2027-05-10 |
| NCT07028112Assistance Publique - Hôpitaux de ParisImpact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogeneic Hematopoietic Stem-Cell Transplantation. | 2027-08-20 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies in Graft vs Host Disease with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Purpose : to evaluate the efficacy of ECP in children with refractory acute GVHD This study addresses patients with persistent GVHD after steroid and/or monoclonal antibody therapy
One arm. Six sessions in two weeks. Classification in complete response (resolution of all signs of GVHD), partial response (improvement of at least one grade) or absence of response (Glucksberg criteria). Tapering depending on patient condition during weeks 2 to 10. Final evaluation at week 10. Steroid therapy tapering at the discretion of the investigator.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECP (performed on Thermos UVAR-XTS or external UVA irradiator after cell collection by apheresis)
GVHD grading
Time frame: during weeks 2 to 10
Overall survival Incidence of chronic GVHD
Time frame: during weeks 2 to 10
Ran from Jun 2009 to primary completion in Jan 2014, 55 months.
Of 86 non-industry phase 2 interventional studies under Graft vs Host Disease, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 116. This study's 55 months is close to that.
Counting every sponsor, half of 103 studies reached it within 52 months; a quarter within 29 and three quarters within 87.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Jun 2012 → Jan 2014 and completion Dec 2012 → Dec 2014.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Sauret A, Rabiau N, Rochette E, Greze V, Halle P, Ouachee M, Dalle JH, Seror E, Serraz D, Yakouben K, Adjaoud D, Pagnier A, Marie-Cardine-Bobbia A, Oudot C, Cu…PubMed 26855157 ↗
Sauret A, Rabiau N, Rochette E, Greze V, Halle P, Ouachee M, Dalle JH, Seror E, Serraz D, Yakouben K, Adjaoud D, Pagnier A, Marie-Cardine-Bobbia A, Oudot C, Cu…PubMed 26855157 ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand →